Tutorials
AN2 Therapeutics Inc logo

AN2 Therapeutics Inc

$ 19.38 +7.61 (+64.66%) 08:09 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 376.02M
Enterprise V:
$ 257.70M
Volume:
248.14K
Avg Vol (2M):
61.72K
Volume:
248.14K
Market Cap $:
376.02M
PE Ratio:
At Loss
Avg Vol (2-Month):
61.72K
Enterprise Value $:
257.70M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

AN2 Therapeutics Inc
NAICS : 325412 SIC : 2834
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -0.73
Interest Coverage No Debt
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 96.5
9-Day RSI 91.49
14-Day RSI 84.75

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.7
Quick Ratio 17.7
Cash Ratio 17.25

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROA % -61.95
ROIC % -655.45
ROCE % -66.69

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -11.95
EV-to-EBITDA -11.95
EV-to-FCF -12.58
Earnings Yield (Greenblatt) % -8.37

Financials (Next Earnings Date:2022-08-31 Est.)

ANTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ANTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.53
Beta 0
Volatility % 0
14-Day RSI 84.75
14-Day ATR ($) 1.826636
20-Day SMA ($) 9.616
12-1 Month Momentum % 0
52-Week Range ($) 6.8789 - 23.58
Shares Outstanding (Mil) 19.4

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

AN2 Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More